Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

British Journal of Haematology

Volumn 126, Issue 5, 2004, Pages 665-674

  Bakkus, Marleen H C ^a   Bouko, Yasmina ^b   Samson, Diana ^c   Apperley, Jane F ^c   Thielemans, Kris ^d   Van Camp, Benjamin ^d   Benner, Axel ^e   Goldschmidt, Hartmut ^f   Moos, Marion ^f   Cremer, Friedrich W ^f  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Minimal residual disease; Multiple myeloma; Prognostic factors; Quantitative polymerase chain reaction; Transplantation

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TIME;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENES, IMMUNOGLOBULIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 4544274208     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05120.x     Document Type: Article

References (46)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
2. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495-2502.
3. Aubin, J., Davi, F., Nguyen-Salomon, F., Leboeuf, D., Debert, C., Taher, M., Valensi, F., Canioni, D., Brousse, N., Varet, B., Flandrin, G. & Macintyre, E.A. (1995) Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia, 9, 471-479.
4. Badros, A., Barlogie, B., Siegel, E., Cottler-Fox, M., Zangari, M., Fassas, A., Morris, C., Anaissie, E., Van Rhee, F. & Tricot, G. (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. Journal of Clinical Oncology, 20, 1295-1303.
5. Bakkus, M.H., Heirman, C., Van, R.I., Van Camp, B. & Thielemans, K. (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood, 80, 2326-2335.
6. Bakkus, M.H., Asosingh, K., Vanderkerken, K., Thielemans, K., Hagemeijer, A., De Raeve, H. & Van Camp, B. (2001) Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia, 15, 1127-1132.
7. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
8. Bouko, Y., Goldscmidt, H., Feremans, W., Bourhis, J.-H., Szydlo, R., Greinix, H., Pico, J., Apperley, J., Gahrton, G. & Samson, D. (2002) Oligoclonal reconstitution after high-dose therapy with PBCT in myeloma patients: implications for assessment of remission status. Bone Marrow Transplantation, 29(Suppl. 2), S102.
9. + selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma shows no significant clinical benefit at 4 years: an EBMT Phase III Randomized Study. Blood, 102, 988a.
10. Buonamici, S., Ottaviani, E., Testoni, N., Montefusco, V., Visani, G., Bonifazi, F., Amabile, M., Terragna, C., Ruggeri, D., Piccaluga, P.P., Isidori, A., Malagola, M., Baccarani, M., Tura, S. & Martinelli, G. (2002) Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 99, 443-449.
11. Cave, H., Van Der Werff, T.B., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. New England Journal of Medicine, 339, 591-598.
12. Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R.M., Benni, M., Pagliani, G., Bandini, G. & Tura, S. (2000) Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood, 96, 355-357.
13. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
14. Cooke, G.P. & Tomlinson, I.M. (1995) The human immunoglobulin VH repertoire. Immunology Today, 16, 237-242.
15. Cooke, F., Bakkus, M., Thielemans, K., Pico, J.L., Apperley, J.F. & Samson, D. (1999) Use of quantitative ASO-PCR to predict relapse in multiple myeloma. British Journal of Haematology, 105, 317-319.
16. Corradini, P., Cavo, M., Lokhorst, H., Martinelli, G., Terragna, C., Majolino, I., Valagussa, P., Boccadoro, M., Samson, D., Bacigalupo, A., Russell, N., Montefusco, V., Voena, C. & Gahrton, G. (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood, 102, 1927-1929.
17. Cremer, F.W., Kiel, K., Wallmeier, M., Goldschmidt, H. & Moos, M. (1997) A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Annals of Oncology, 8, 633-636.
18. Cremer, F.W., Kiel, K., Wallmeier, M., Haas, R., Goldschmidt, H. & Moos, M. (1998) Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Experimental Hematology, 26, 969-975.
19. Cremer, F.W., Ehrbrecht, E., Kiel, K., Benner, A., Hegenbart, U., Ho, A.D., Goldschmidt, H. & Moos, M. (2000) Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplantation, 26, 851-858.
20. Davies, F.E., Forsyth, P.D., Rawstron, A.C., Owen, R.G., Pratt, G., Evans, P.A., Richards, S.J., Drayson, M., Smith, G.M., Selby, P.J., Child, J.A. & Morgan, G.J. (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. British Journal of Haematology, 112, 814-819.
21. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008-4010.
22. Durie, B.G., Stock-Novack, D., Salmon, S.E., Finley, P., Beckord, J., Crowley, J. & Coltman, C.A. (1990) Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood, 75, 823-830.
23. Fassas, A.B., Spencer, T., Sawyer, J., Zangari, M., Lee, C.K., Anaissie, E., Muwalla, F., Morris, C., Barlogie, B. & Tricot, G. (2002) Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology, 118, 1041-1047.
24. Goldschmidt, H., Martin, H., Serke, S., Hegenbart, U., Glasmacher, A., Ko, Y., Meyer, K.-R., Schultze, W., Rudolph, C., Gerhartz, H., Hastka, J., Wilhelm, M., Gieseler, F., Ehninger, G., Hehlmann, R., Hoelzer, D., Huhn, D., Haas, R. & Ho, A.D. (1998) Tandem autologous transplantation (tpx) for multiple myeloma (MM): results of a German multicenter study. Blood, 92, 662a.
25. Goldschmidt, H., Cremer, F.W., Hegenbart, U., Benner, A., Haas, R., Moos, M. & Ho, A.D. (1999) Comparison of 3 high-dos regimens with autologous peripheral blood stem cell transplantation (TPX) for multiple myeloma (MM): a single center experience in 230 patients (PTS). Journal of Clinical Oncology, 18, 5a.
26. Greipp, P.R., Katzmann, J.A., O'Fallon, W.M. & Kyle, R.A. (1988) Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood, 72, 219-223.
27. Holländer, N., Sauerbrei, W. & Schumacher, M. (2001) Estimating the effect of a prognostic or risk factor after selection of an 'optimal' cutpoint. Freiburg Center for Data Analysis and Modeling (FDM-Preprint 73, pdf, 200k). URL http://www.fdm.uni-freiburg.de/ groups/medstat/valid/ HollSaueSchu2001-preprint73.pdf.
28. Hovenga, S., de Wolf, J.T., Guikema, J.E., Klip, H., Smit, J.W., Smit Sibinga, C.T., Bos, N.A. & Vellenga, E. (2000) Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post-transplantation. Bone Marrow Transplantation, 25, 723-728.
29. Ihaka, R. & Gentlemen, R. (1996) A language for data analysis and graphics. J. Computational Graphic Statistics, 5, 299-314.
30. Korn, E.L. (1986) Censoring distributions as a measure of follow-up in survival analysis. Statistics in Medicine, 5, 255-260.
31. Kyle, R.A. (1994) Why better prognostic factors for multiple myeloma are needed. Blood, 83, 1713-1716.
32. Lahuerta, J.J., Martinez-Lopez, J., Serna, J.D., Blade, J., Grande, C., Alegre, A., Vazquez, L., Garcia-Larana, J., Sureda, A., Rubia, J.D., Conde, E., Martinez, R., Perez-Equiza, K., Moraleda, J.M., Leon, A., Besalduch, J., Cabrera, R., Miguel, J.D., Morales, A., Garcia-Ruiz, J.C., Diaz-Mediavilla, J. & San Miguel, J. (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 109, 438-446.
33. Lausen, B. & Schumacher, M. (1992) Maximally selected rank statistics. Biometrics, 48, 73-85.
34. Lemoli, R.M., Martinelli, G., Zamagni, E., Motta, M.R., Rizzi, S., Terragna, C., Rondelli, R., Ronconi, S., Curti, A., Bonifazi, F., Tura, S. & Cavo, M. (2000) Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood, 95, 2234-2239.
35. Maloney, D.G., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F.R., Blume, K.G., Forman, S.J., McSweeney, P. & Storb, R. (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 102, 3447-3454.
36. Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R.M., Bandini, G., Motta, M.R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S. & Cavo, M. (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of Clinical Oncology, 18, 2273-2281.
37. Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M. & Pileri, A. (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 94, 673-683.
38. Mateo, G., Orfao, A., Montalban, M.A., Bladé, J., Lahuerta, J.J. & San Miguel, J.F. (2003) Immunophenotypic investigation of minimal residual disease in multiple myeloma (Abstract). The Hematology Journal, 4, S48.
39. Olavarria, E., Kanfer, E., Szydlo, R., Kaeda, J., Rezvani, K., Cwynarski, K., Pocock, C., Dazzi, F., Craddock, C., Apperley, J.F., Cross, N.C. & Goldman, J.M. (2001) Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 97, 1560-1565.
40. Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y. & Matsumoto, T. (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood, 90, 3179-3186.
41. Schumacher, M., Holländer, N., Schwarzer, G. & Sauerbrei, W. (2001) Prognostic factor studies. In: Handbook of Statistics in Clinical Oncology (ed. by J. Crowley), pp. 321-378. Marcel Dekker, New York.
42. Singhal, S., Powles, R., Milan, S., Raje, N., Viner, C., Treleaven, J., Raymond, J., Cunningham, D. & Mehta, J. (1995) Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplantation, 16, 537-540.
43. Swedin, A., Lenhoff, S., Olofsson, T., Thuresson, B. & Westin, J. (1998) Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. British Journal of Haematology, 103, 1145-1151.
44. Taswell, C. (1981) Limiting dilution assays for the detection of immunocompetent cell frequencies. Journal of Immunology, 126, 1614-1619.
45. Vescio, R.A., Han, E.J., Schiller, G.J., Lee, J.C., Wu, C.H., Cao, J., Shin, J., Kim, A., Lichtenstein, A.K. & Berenson, J.R. (1996) Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplantation, 18, 103-110.
46. Willems, P., Verhagen, O., Segeren, C., Veenhuizen, P., Guikema, J., Wiemer, E., Groothuis, L., Jong, T.B., Kok, H., Bloem, A., Bos, N., Vellenga, E., Mensink, E., Sonneveld, P., Lokhorst, H., van Der, S.E. & Raymakers, R. (2000) Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood, 96, 63-70.